Diabetes mellitus is a potentially life-threatening disease affecting major populations worldwide. Epidemiological studies and clinical trials strongly support that hyperglycemia is the principal cause of microvascular (retinopathy, neuropathy, nephropathy) and macrovascular (heart disease, stroke, amputations) complications, 1) suggesting effective blood glucose control as the key to preventing or reversing diabetic complications and improving quality of life in patients with diabetes.
1.2 mM MgSO 4 , 20 mM NaHCO 3 , 16 mM HEPES and 0.3% bovine serum albumin, pH 7.4]. Cells were then treated with KRB buffer containing 5 mM glucose with or without CK, and incubated for 1 h at 37°C. After incubation, aliquots of the media were stored at Ϫ20°C until insulin measurement. To explore how CK augments the glucose-stimulated insulin secretion, HIT-T15 cells were incubated for 1 h in KRB buffer containing either 0.5 mM diazoxide or 10 mM nifedipine in the absence or presence of CK (8 mM) , and insulin concentration was measured.
Oral Glucose Tolerance Test (OGTT) in ICR Mice The ICR mice were fasted for 12 h prior to the experiment, and CK (12.5, 25 mg/kg) was administered orally 30 min prior to glucose challenge. Glucose (1.5 g/kg) was orally administered at 0 min, and the blood was withdrawn at 0, 30, 60 and 120 min after glucose administration. Plasma glucose and insulin levels were determined by the glucose oxidase method and mouse insulin ELISA kit, respectively.
Anti-diabetic Effects in db/db Mice. Animals Fiveweek-old male C57BL/KsJ db/db mice were purchased from Japan SLC, Inc. (Hamamatsu, Japan) and were acclimatized in a room with 12-12 h light-dark cycle (8:00 A.M. to 8:00 P.M.), a temperature of 24Ϯ1°C, and a humidity of 55Ϯ5%. Throughout the experimental period, animals were fed with standard rodent chow (LabDiets, U.S.A.) and water ad libitum. At seven-week-old, mice were randomly divided into four groups; diabetic control group (DC) and three treatment groups. Compound K was given at a dose of 10 mg/kg (CK), metformin at 150 mg/kg (MET) and the same dosage of each drug was applied to compound K plus metformin combination group (CKϩMET). Body weight and blood glucose levels were measured every week. At the end of the study, blood was collected for plasma insulin, adiponectin and lipid level measurement. After sacrifice, liver was immediately removed and instantly soaked in liquid nitrogen and stored at Ϫ70°C for morphological examination.
Hemoglobin A1c Using blood samples collected from db/db mice in the fasting state, percent HbA1c was measured with a Hemoglobin A1c kit according to the manufacturer's instructions.
Insulin and HOMA-IR Mouse insulin enzyme immunoassay ELISA kit was used to measure the plasma insulin concentration. Insulin resistance was determined by the homeostasis model assessment (HOMA) method by using the following equation: HOMA value for insulin resistance (HOMA-IR)ϭfasting insulin (mU/ml)ϫfasting glucose (mmol/ l)/22.5.
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Hepatic Histology Liver was removed and fixed in 10% neutral buffered formalin. The tissues were subsequently embedded in paraffin and sectioned with thickness of 5 mm using a microtome (Leica, Wetzlar, Germany). Tissue sections prepared onto aminosilane-treated slides were deparaffinized and rehydrated through graded alcohols to distilled water. Tissue sections were stained with hematoxylin-eosin and mounted with Canada balsam before analyzing under microscope (Olympus, Japan 
RESULTS

Effect of CK on Insulin Secretion
To explore whether CK augments a glucose-stimulated insulin secretion, different concentrations of CK were treated to HIT-T15 cells. CK at the concentration range between 1 and 8 mM augmented a glucose-stimulated insulin secretion in a concentration dependent manner with the maximal response occurring at 8 mM (Fig. 1A) . Next, to examine how CK enhances a glucose-stimulated insulin secretion, diazoxide (K ϩ channel opener) and nifedipine (L-type of Ca ϩ2 channel blocker) were used. Diazoxide (0.5 mM) blocked a glucose-induced insulin secretion from 31.9Ϯ2.7 to 15.4Ϯ1.2 mU/ml in HIT-T15 cells (pϽ0.01, Fig. 1B) . In HIT-T15 cells supplemented with 5 mM glucose and 8 mM CK, diazoxide suppressed the insulin secretion to a level observed in 5 mM glucose with diazoxide (pϽ0.001). The addition of 10 mM nifedipine also reduced the insulin secretory effect of CK from 47.5Ϯ2.5 to 19.3Ϯ0.6 mU/ml (pϽ0.001, Fig. 1B) , to a level observed in cells incubated with 5 mM glucose and nifedipine (18.5Ϯ 2.0 mU/ml).
OGTT in ICR Mice OGTT was performed to determine the effect of a single oral dose of CK on glucose tolerance and insulin secretion using the ICR mice ( Fig. 1 ). Glucose challenge dramatically increased the blood glucose levels in control group mice, whereas CK-treated groups significantly prevented the blood glucose levels from rising, especially at 30 min after glucose load (pϽ0.05, Fig. 1C ). When the area under the curve (AUC) was compared between groups, CK12.5 and CK25-treated groups (12.5, 25 mg/kg dose) showed 9% and 15% (pϽ0.05) reduction, respectively, compared to that of control group (inset at upper right corner of Fig. 1C ). Plasma insulin level at 30 min after glucose load in control group was 31.9Ϯ0.8 mU/ml, whereas insulin levels in CK12.5 and CK25-treated groups were 35.8Ϯ1.8 (pϽ0.05) and 37.5Ϯ1.1 mU/ml (pϽ0.01), respectively, indicating that CK lowered the blood glucose levels by enhancing insulin secretion (Fig. 1D) .
Effects of CK, MET and CK؉MET on Metabolic Parameters Table 1 shows the effects of CK, MET and CKϩ MET on metabolic parameters in diabetic db/db mice treated for 8 weeks. Compared to DC, weight gain was decreased in both CK and MET groups; however, this decrease in weight gain was not observed in CKϩMET combination group. All treatment groups showed increase in food intake, and water intake was increased in CKϩMET group compared to DC. The HbA1c levels of treatment groups were all significantly lower than that of DC. With HbA1c level 5.9Ϯ0.2% in DC, CK showed 4.9Ϯ0.5% (pϽ0.01), 4.9Ϯ0.2% for MET (pϽ 0.01) and 5.0Ϯ0.1% for CKϩMET (pϽ0.01). The plasma adiponectin level was also determined at the end of the experiment. Although all treatment groups showed increase in the plasma adiponectin levels compared to DC, only CK group showed the significance. At the end of the experiment, mice were sacrificed and their liver and fat tissues were removed. When the epididymal fat was weighed, significant difference in fat weight/body weight (%) was observed in MET (5.4Ϯ0.4%, pϽ0.01) compared to DC (6.3Ϯ0.5%). The plasma lipid levels triglyceride, cholesterol, HDL-cholesterol and LDL-cholesterol levels were also determined; however, no significant differences were observed.
Effects of CK, MET and CK؉MET on Plasma Glucose, Insulin and Insulin Resistance Index
The effects of CK, MET and CKϩMET on plasma glucose, insulin and HOMA value for insulin resistance in diabetic db/db mice are shown in Table 2 . When the plasma glucose levels were measured at the end of the experiment, all treatment groups [CK; 7.5Ϯ0.6 mM (pϽ0.01), MET; 7.5Ϯ0.5 mM (pϽ0.01), CKϩMET; 7.1Ϯ0.4 mM (pϽ0.001)] showed significantly decreased plasma glucose levels compared to DC (10.5Ϯ 0.8 mM) with CKϩMET treatment group being the most effective. The plasma insulin level was also detected. Compared to 405.9Ϯ27.5 mU/ml in DC, the plasma insulin concentrations of CK, MET and CKϩMET were 309.6Ϯ44.7 mU/ml, 167.2Ϯ10.4 mU/ml (pϽ0.05) and 65.5Ϯ17.9 mU/ml (pϽ0.05), respectively. With the plasma glucose and insulin levels in each group, insulin resistance index was calculated 
Effects of CK, MET and CK؉MET on Liver/Body Weight Ratio and Hepatic Histology
To examine the effects of CK, MET and CKϩMET administration on the liver of diabetic db/db mice, the weight of liver tissue was measured and the liver weight/body weight (%) ratio was calculated. MET and CKϩMET showed statistically significant differences when compared to the DC (pϽ0.01) (Fig. 2A) . The hematoxylin and eosin-stained paraffin sections of liver tissues from DC, CK, MET and CKϩMET groups are shown in Fig. 2B . Large lipid droplets are observed in the DC group. These lipid droplets are observed less in the treatment groups, especially in the CKϩMET combination group.
DISCUSSION
Compound K (CK) is a final metabolite of protopanaxadiol ginsenosides. Although panax ginseng is known to have anti-diabetic activity, the active ingredient is not yet fully identified. In our preliminary studies, protopanaxadiol ginsenosides showed the insulin secretion-stimulating activity. Therefore, it would be interesting to know whether and how CK has an anti-diabetic activity. In vitro studies using HIT-T15 cells, CK enhanced the insulin secretion in a concentration dependent manner (Fig. 1A) . This effect, however, was completely abolished in the presence of diazoxide or nifedipine (Fig. 1B) . Insulin secretion-stimulating activity of a single oral CK administration was also confirmed in OGTT using ICR mice (Figs. 1C, D) . From these studies, we may conclude that CK lowered the plasma glucose level by stimulating an insulin secretion and this action was presumably due to the blockade of ATP sensitive K ϩ channel. Metformin (MET), a biguanide that reduces hyperinsulinemia and improves hepatic insulin resistance, 22, 23) is used as an oral anti-hyperglycemic agent to treat type 2 diabetics. Although metformin became available for diabetes in the 1950s the mechanism by which it improves insulin sensitivity remained unclear until finding that metformin activates AMPactivated protein kinase (AMPK) 24) and inhibits mitochondrial respiratory complex I, 25) mitochondrial permeability transition 26) and tyrosine phosphatase activity.
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The aim of this study was to firstly compare the efficacy of CK and MET and secondly to assess the effects of its combination in diabetic db/db mice. As shown in Tables 1 and 2 , plasma glucose and hemoglobin A1c in CK (10 mg/kg) and MET (150 mg/kg) monotherapy groups were comparable. Plasma insulin level, on the other hand, was significantly low in the MET treated group, compared to CK, resulting in low HOMA-IR index. Furthermore, it is worth noticing that CKϩMET combination therapy showed remarkably low plasma insulin level and HOMA-IR index. Action mechanism(s) for this marked reduction of plasma insulin level in combination group remains to be established. However, we also found that CK treatment ameliorated an insulin resistance through suppressions of endogenous glucose production (unpublished microarray and enzyme activities data) and lipogenesis in the liver (Fig. 2) . In addition, CK has been shown to activate phosphorylation of AMPK in the HIT-T15 cells (unpublished result). With these observations, we speculate that CKϩMET group could lower plasma insulin level and consequently HOMA-IR index more effectively than each drug alone.
Type 2 diabetes strikes 3-7% of adults in most westernized societies, and more than 160 million people worldwide. Rendered by an increasing obesity epidemic, the prevalence of type 2 diabetes is expected to more than double in the next 25 years creating a major healthcare challenge. 28) Insulin resistance is an early and sustained feature of type 2 diabetes. 29) When insulin concentrations are insufficient to compensate for insulin resistance, then hyperglycemia comes about. A therapeutic strategy to address both the hyperglycemia and the insulin resistance is, therefore, rational. Recently, the importance of reducing not only fasting hyperglycemia, but also postprandial hyperglycemia, has been proposed. Postprandial hyperglycemia has shown to be an independent risk factor for the development of macrovascular complications. 30) Now, combining an insulin secretion enhancer with an insulin sensitizer is considered to increase effectiveness of hyperglycemia control. Given these circumstances, it is reasonable to consider the combination of an insulin secretion enhancer (compound K) and an insulin sensitizer (metformin) as a candidate to control hyperglycemia effectively.
Compared to monotherapy, CKϩMET combination therapy was more effective in lowering plasma glucose level, plasma insulin concentration and HOMA-IR index. These results raise the possibility that CKϩMET combination may be valuable for improving diabetic conditions efficiently. Combination treatment of CK and MET at different concentrations; for example, CK 20 mg/kg and MET 300 mg/kg, may also be taken into consideration for this may lead to finding the optimal dosage with the optimal effect.
Almost a quarter of adults in many industrialized countries have excessive fat accumulation in the liver. 31) Although the cause of fatty liver is not known, it is often associated with obesity and type 2 diabetes. Lin et al. 32) demonstrated that metformin improved fatty liver disease, reversing hepatomegaly, steatosis and aminotransferase abnormalities. We also examined the effects of CK, MET and CKϩMET on fatty liver disease in db/db mice. After 8 weeks of treatment, the liver/body weight ratio was markedly reduced in CKϩ MET treated group, when compared to the CK or MET alone group ( Fig. 2A) . Hepatic histology also demonstrated that steatosis presented in the control mice has virtually disappeared from the livers of CKϩMET treated mice (Fig. 2B) . Therefore, addition of CK (i.e. CKϩMET combination therapy) has shown to enhance the beneficial effect metformin has on the liver, suggesting the possibility of its use along with metformin on non-alcoholic fatty liver disease.
In summary, this comparative study shows that anti-hyperglycemic effects of CK and MET are comparable with doses of 10 and 150 mg/kg, respectively. In addition, the combination of CK and MET improved the plasma glucose and insulin levels, resulting in HOMA-IR index more efficiently, suggesting that a combination of CK and MET may be very useful in clinical practice for the effective improvement of hyperglycemia and insulin resistance.
